Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the Sky Bioscience 3rd Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. I would now like to turn the conference over to Bernie Hertel, Head of Investor Relations. Please go ahead. Hello, and thank you all for participating in today's call. Joining me today is Puneet Dhillon, Sky's President and CEO, and Caitlin Arsenault, Sky's CFO. Before we begin, I'd like to caution that comments made during this conference call will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Sky's expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Puneet Dhillon. Good afternoon, everyone. Thank you for joining us on Sky's first earnings call, and we appreciate your continued interest in Sky and your support for our journey focused on developing metabolic medicine that we believe is relevant to the market and has the potential to be impactful for patien...